Finance

KeyBanc Downgrades Rocket Lab Stock Amidst Fully Priced Growth Prospects

Despite Leading Market Position, Rocket Lab Faces Investor Caution Over Valuation and Launch Milestones

Rocket Lab Corp. experienced its first stock downgrade in over 18 months as KeyBanc Capital Markets revised its rating from Overweight to Sector Weigh...

Ocugen Reports Promising Phase 2 Gene Therapy Results in Vision Loss Reduction

Preliminary data reveal significant lesion size decrease for OCU410 in geographic atrophy patients, with ongoing plans for pivotal trials and regulatory submissions

Ocugen, Inc. has disclosed encouraging early outcomes from its Phase 2 clinical study evaluating OCU410, a gene therapy for geographic atrophy, demons...

Ripple’s $150 Million Investment and ETF Inflows Could Pave Way for XRP’s Rally to $3

After multiple technical hurdles and a recent strategic stablecoin deal, XRP shows potential for breakout amid shifting market dynamics

XRP faces critical technical challenges after four unsuccessful attempts to surpass a descending resistance trendline since July. Despite this, new de...

STAAR Surgical Faces Share Price Decline Amid Major Board Overhaul Driven by Broadwood Partners

Significant governance changes follow Broadwood Partners’ increased influence as it holds nearly one-third ownership

Shares of STAAR Surgical Company (NASDAQ:STAA) declined amid pivotal alterations in its board composition. Broadwood Partners, STAAR’s largest share...

JPMorgan Launches Quantitative Trading Unit Amid Strong Q4 2025 Financial Results

The bank aims to enhance its electronic trading capabilities while reporting robust earnings and asset growth

JPMorgan Chase & Co. has announced the creation of a new quantitative trading and research group to bolster its electronic trading and data analytics ...

Silver Prices Retrace After Recent Rally: Analyzing the Market Dynamics

Examining the factors behind iShares Silver Trust's recent pullback and what lies ahead for silver investors

Shares of iShares Silver Trust (SLV) have declined from recent peaks amid profit-taking following a strong rally propelled by geopolitical concerns an...

Oscar Health Shares Rally Following ACA Subsidy Continuation and Barclays Reassessment

Legislative actions paired with analyst upgrades lift Oscar Health’s stock amid evolving market dynamics

Oscar Health's stock witnessed a pronounced increase fueled by the U.S. House of Representatives passing a healthcare subsidy extension under the Affo...

State Street Advances Digital Asset Infrastructure Ahead of Earnings Report

Institutional Focused Digital Asset Platform Seeks to Bridge Traditional Finance and Blockchain Systems

State Street Corporation’s shares experienced a moderate increase following the launch of a new digital asset platform designed to integrate tokeniz...

POET Technologies Shares Rally Amid Optimistic Market Trends and Positive Analyst Outlooks

Robust Momentum and Upbeat Projections Propel POET Stock Near 52-Week Highs

Shares of POET Technologies Inc. have experienced significant gains, buoyed by a positive overall market environment and favorable analyst ratings. Th...

ImmunityBio Sees Remarkable Revenue Growth and Robust Market Momentum

Strong sales performance from Anktiva propels ImmunityBio shares to new highs amid positive clinical data

ImmunityBio, Inc. (NASDAQ: IBRX) reported substantial gains in preliminary net product revenue for its FDA-approved immunotherapy Anktiva in fiscal 20...

Johnson & Johnson's Tecvayli Demonstrates Notable Survival Benefit in Multiple Myeloma Patients

Phase 3 MajesTEC-9 trial reveals significant progression-free and overall survival improvements versus standard therapy in relapsed/refractory multiple myeloma

Johnson & Johnson revealed encouraging results from the Phase 3 MajesTEC-9 trial testing Tecvayli (teclistamab-cqyv) monotherapy against standard trea...

OS Therapies Presents Promising Biomarker Data Amid Stock Decline

Clinical trial findings support regulatory progress for OST-HER2 in treating metastatic osteosarcoma

OS Therapies Incorporated disclosed encouraging biomarker outcomes from its Phase 2b trial focused on OST-HER2 for recurrent lung metastatic osteosarc...